Turalio mechanism of action?

How does Turalio (pexidartinib) work?

Turalio (pexidartinib) is a kinase inhibitor. Its mechanism of action is to block multiple tyrosine kinases involved in signaling pathways that drive abnormal growth and inflammation in certain tumors. In particular, it inhibits CSF1R and KIT (among other kinases), which reduces signaling that supports tumor-associated macrophage activity and tumor growth in conditions like tenosynovial giant cell tumor (TGCT). [1]

What role do CSF1R and KIT play in TGCT?

In TGCT, pathways involving macrophage survival and signaling are linked to disease biology. CSF1R is a key receptor in macrophage signaling, and KIT is another kinase involved in relevant cell growth and survival pathways. By inhibiting these receptors, pexidartinib can shift the tumor microenvironment and reduce disease-driving cell activity. [1]

Is Turalio a targeted drug or chemotherapy?

Turalio is a targeted therapy (a small-molecule kinase inhibitor), not traditional cytotoxic chemotherapy. Its effects come from specific inhibition of signaling enzymes (kinases) rather than broad cell-killing. [1]

Source

1. DrugPatentWatch.com (Turalio/pexidartinib drug information page): https://www.drugpatentwatch.com/p/turalio